Medical artificial intelligence (AI) company Lunit (CEO Seo Beom-seok) announced on the 22nd that it will enter into a strategic collaboration with global biotechnology company Agilent Technologies to jointly develop an AI-based companion diagnostic (CDx) solution.
Agilent, a global life sciences company headquartered in California, USA, provides diagnostic and analytical solutions essential for new drug development in the pharmaceutical and biotech industries. As of 2023, Agilent recorded sales of approximately $6.5 billion (approximately 9 trillion won) and is considered a global life sciences company, alongside companies like Thermo Fisher Scientific, Danaher, and Illumina.
This collaboration aims to combine Lunit's AI pathology analysis technology with Agilent's tissue-based diagnostic capabilities to jointly develop and launch a biomarker analysis solution essential for the new drug development process into the global market.
The two companies will initially focus on developing AI solutions for clinical trials, and plan to collaborate with global pharmaceutical companies to obtain approval for companion diagnostics and expand into a commercial model.
Lunit plans to expand its influence in the global precision medicine market centered on products such as its pathology analysis solution, Lunit SCOPE, and use this collaboration as a springboard to strengthen its position in the companion diagnostics field.
“Biomarker analysis is a core area of precision oncology, but much of the analysis is still manual,” said Seo Beom-seok, CEO of Lunit. “The combination of Agilent’s diagnostic platform and Lunit’s AI technology will significantly improve the speed and accuracy of new drug development.”
“Agilent is committed to providing advanced diagnostic solutions to both pharmaceutical companies and patients,” said Nina Green, general manager of Agilent’s Clinical Diagnostics business unit. “Through our collaboration with Lunit, we will develop innovative AI-based companion diagnostic solutions and contribute to the expansion of precision medicine.”
- See more related articles
You must be logged in to post a comment.